Member Exclusive News

The week in industry: Spinal muscular atrophy treatment gets positive recommendation from NICE

This week: Vertex Pharmaceuticals and Kymera Therapeutics (both MA, USA) enter into a four-year collaboration to develop protein targeted therapies, the US FDA approves the first combination PD-L1 therapy for advanced renal cell carcinoma and Vaccitech (Berlin, Germany) is granted access to ProBioGen’s (Oxford, UK) vaccine manufacturing production platform.

Go to the profile of RxNet
May 16, 2019
0
0

Please sign in or register for FREE

No comments yet.